Moderna's Cancer Vaccine, Respiratory Business and Cash-Flow Valuation
A clinical breakthrough changes the opportunity. It doesn't settle the valuation.
Moderna has positive Phase 3 melanoma evidence at a time when respiratory vaccines still account for nearly all commercial product sales. The shares imply an approximately $88.16B equity value at the November 2 close. The cash the company could keep depends on vaccine demand, individualized treatment economics, future research spending and how profits are divided with Merck.
Respiratory vaccine sales have not yet replaced the COVID peak
Revenue fell from $3.236B in 2024 to $1.944B in 2025. COVID vaccines still supplied $1.810B in product sales. RSV contributed only $8M. These are real businesses with approvals and distribution, but reported sales have not yet established a diversified vaccine franchise. FY2025 Form 10-K.
COVID remained the product-sales engine in 2025
In 2025 Moderna reported about 1.81 billion dollars in COVID product sales and 8 million dollars in RSV product sales.
Europe explained much of the first-half product-sales increase
H1 U.S. product revenue moved from 119 to 143 million dollars, Europe from zero to 255 million, and the rest of the world from 81 to 48 million.
mNEXSPIKE may strengthen Moderna's share of the seasonal COVID market, but overall vaccination rates, net prices and competition matter more than the posted price of a dose. mRESVIA has approval but little recorded revenue so far. MFLUSIVA gained FDA approval in August 2026 for adults 50 and older. The key test for flu is whether a newly launched product can win contracts against established manufacturers; approval alone does not establish market share. FDA approval record.
The melanoma trial reduced clinical risk; commercialization remains unproven
The randomized INTerpath-001 Phase 3 trial included 1,137 patients with resected high-risk melanoma. At 24 months, recurrence-free survival was 82.2% with intismeran plus Keytruda versus 70.0% with Keytruda alone. The relative hazard reduction for recurrence or death was 42%; overall survival results were still immature. Merck and Moderna trial results; ESMO clinical analysis.
Two-year recurrence-free survival in INTerpath-001
At 24 months, recurrence-free survival was 82.2 percent with intismeran and Keytruda compared with 70.0 percent with Keytruda alone. The hazard ratio was 0.58.
The trial result does not reveal the size of a paying customer base. The commercial population must be narrowed from total melanoma incidence to surgically treated high-risk patients eligible for the studied regimen. Tumor sequencing, personalized manufacturing time, treatment adoption and insurer coverage can all reduce actual utilization. We use explicit patient and price assumptions rather than assigning every melanoma diagnosis to the product.
One possible peak-year melanoma revenue bridge
The central case assumes 8,100 U.S. patients at 150,000 dollars per course and 7,500 patients outside the U.S. at 95,000 dollars. This would be about 1.93 billion dollars of product revenue worldwide, before costs and approximately equal partner profit sharing.
- United States8,100 patients × $150,000$1.215B therapy revenue
- Outside the U.S.7,500 patients × $95,000$0.713B therapy revenue
- Worldwide therapy sales$1.927BBefore personalized manufacturing and selling costs
- Operating profit available to share~55% margin in the central assumptionAfter modeled manufacturing and commercialization costs, before separate development spending
- Moderna collaboration economicsApproximately 50% of partner profitNot 50% of Keytruda sales; net present value also reflects delays, tax, trial risk and future spending
Merck generally shares intismeran collaboration costs and profits equally with Moderna, subject to agreement terms. Keytruda belongs to Merck and is not added to Moderna revenue. Our central melanoma risk-adjusted present value is $1.01B; other nonoverlapping oncology programs reduce the combined central rNPV to $0.24B because their expected development costs exceed the weighted expected commercial cash flows. Positive melanoma data do not establish the efficacy of lung, bladder or kidney programs.
Three vaccine paths produce very different cash flows
The forecast distinguishes COVID vaccination, RSV, standalone flu and combination products, international agreements, and a small other-revenue line. No oncology commercialization is counted in these revenue series. The wide range measures commercial uncertainty, not statistical confidence bounds.
Vaccine and other non-oncology revenue through 2036
2027 vaccine and other revenue is 1.6 billion dollars in bear, 2.5 billion base and 4.0 billion bull. By 2036 it reaches 1.5, 6.8 and 16.0 billion dollars respectively.
How much economic cash remains after operating costs and reinvestment?
Annual modeled after-tax cash flow in the base case is negative 2.05 billion dollars in 2027 and positive 1.04 billion in 2036. In 2036 the bear model stays negative at 0.56 billion dollars, while the bull model reaches 5.39 billion dollars.
R&D is a recurring economic expense. The model leaves stock-based pay in costs and deducts manufacturing, commercialization, working capital and capital expenditure. It keeps Moderna's oncology program spending in the oncology valuation rather than deducting it a second time from the vaccine cash flows. A future drug discovery breakthrough could add value, but the forecast does not insert undiscovered medicines as an unexplained terminal premium.
The June balance sheet cannot simply be used with a November stock price
At June 30, Moderna held $6.91B in cash and investments and $600M of term-loan principal. The company subsequently paid a $950M patent settlement and issued $3B of zero-coupon convertible notes. The notes provided new financing cash but created a creditor claim and potential conversion economics. June filing; September notes disclosure.
From summer guidance to provisional year-end net financial assets
The midpoint of 2026 year-end cash guidance was 4.95 billion dollars. Adding 2.6285 billion of financing cash after capped-call costs gives around 7.58 billion. Deducting 600 million of term debt and 3 billion of convertible principal leaves about 3.98 billion of provisional net financial assets.
- Midpoint of July year-end cash guidance$4.95BThe guidance already anticipates the July settlement, subject to operating outcomes
- September financing cash, net of capped-call purchase+$2.63B$2.957B net proceeds less $0.329B capped-call premium
- Provisional cash and investments at year-end$7.58BNot a company-reaffirmed forecast
- Term loan and convertible principal−$3.60BDebt convention; full conversion shares are not simultaneously added
- Provisional net financial assets$3.98BSubject to cash timing, dilution, contingent payments and note settlement
The stated cash-flow scenarios do not reach the November equity value
The vaccine and remaining corporate business is discounted over 2027–2036. A terminal value is applied only if core cash flow can support one; modeled oncology cash flows extend through 2045 without an additional oncology perpetuity. Costs for the same oncology programs are charged once. Different cash-flow paths—not one assumed fair price—drive the gap.
Equity values from modeled activities versus November 2 capitalization
Modeled central equity is 5.08 billion dollars, modeled bull equity is 40.51 billion, and the dated equity market value is 88.16 billion. Bear continuation economics are negative.
What creates the central modeled equity value?
Ten-year core cash flow present value is negative 2.56 billion dollars, core terminal value 3.43 billion, oncology risk-adjusted present value 0.24 billion, and provisional net cash 3.98 billion, for central modeled equity of 5.08 billion.
- Core cash flow, 2027–2036−$2.56BDiscounted operating cash flow net of reinvestment
- Core value after 2036$3.43BConditional on 10% core discount rate and 1.5% long-run growth
- Modeled oncology program rNPV$0.24BIndication-specific expected cash flows discounted at 10.5%
- Provisional net cash$3.98BCash less term loan and convertible principal
- Central modeled equity$5.08BAbout $12.74 per quoted basic share; not a price target
In the bear continuation case, discounted operating losses exceed provisional net cash, so the model produces negative economic equity. A publicly traded share cannot have a negative market price; the figure describes an unfavorable continuation strategy, not liquidation recovery. The optimistic case assumes $16B in vaccine and other non-oncology revenue by 2036, alongside successful oncology commercialization. Even that path remains below the dated market value.
How discount rate and terminal growth change the central result
At a 10 percent core discount rate, model value is 11.34 dollars per share at zero terminal growth, 12.74 dollars at 1.5 percent, and 13.98 dollars at 2.5 percent. All values remain below the November 2 close.
| Core discount rate | 0% growth | 1.5% growth | 2.5% growth |
|---|---|---|---|
| 8.5% | $13.86 | $16.12 | $18.25 |
| 10.0% | $11.34 | $12.74 | $13.98 |
| 12.0% | $9.18 | $9.98 | $10.70 |
What would the market price require?
At $220.83 and approximately 399.24M shares, the quoted equity value is $88.16B. Removing the provisional net financial assets leaves $84.18B of implied operating value. Holding the central ten-year cash-flow path and modeled oncology value unchanged, the required sustainable core free cash flow starting in 2037 is about $19.07B annually, versus approximately $0.74B normalized for the central 2036 cash-flow starting point.
The reverse DCF turns a share price into a future cash requirement
The November 2 basic market capitalization was 88.16 billion dollars. After 3.98 billion provisional net cash, the market implied 84.18 billion of operating value. With central near-term cash flows and oncology value held fixed, the residual requires 19.07 billion of recurring core free cash flow beginning in 2037.
- Dated equity market value$88.16BShare price × quoted basic shares
- Less provisional net financial assets−$3.98BDebt-convention financing adjustment
- Market-implied operating value$84.18BValue that must be generated by operations and pipeline assets
- Hold central explicit cash flows and oncology rNPV fixed2027–2036 + modeled oncologyAll missing present value is assigned to future core cash flows
- Sustainable 2037 core FCF required$19.07BAt 10% discount rate and 1.5% perpetual core growth
More early oncology profits, expanded indications, higher vaccine margins or valuable medicines absent from the current model could reduce that terminal requirement. Conversely, unsuccessful launches, reimbursement limits, delayed approvals, dilution or spending overruns would make the cash-flow hurdle harder to reach. The reverse DCF measures expectations embedded in a price; it cannot assign a reliable probability to outcomes that have yet to be observed.
What evidence would change the calculation?
- Third-quarter financial resultsNovember 6, 2026Seasonal vaccine sales, cash, costs and 2026 guidanceReplace the provisional cash bridge and dated revenue baseline with filed data.
- Flu and RSV commercialization2026–2028Procurement, real doses, recognized prices and gross marginsApproval matters, but repeat purchasing and profitable distribution decide cash flow.
- Intismeran regulatory decisionDate not establishedCommercial label, treatment population and manufacturing capacityClinical benefit must translate into deliverable, reimbursed therapy courses.
- Other oncology studiesMulti-yearIndication-specific trial resultsMelanoma success does not automatically make lung, renal or bladder trials succeed.
Research data
- Download CSVCSVCSV downloadThirty annual vaccine and risk-adjusted oncology cash-flow observations for 2027–2036 across three illustrative paths.Data snapshot November 3, 2026 · Reuse with attribution to the canonical study.
- Download JSONJSONJSON downloadScenario assumptions, dated historical references, financing estimates, modeled patient economics, valuation bridges and caveats.Data snapshot November 3, 2026 · Reuse with attribution to the canonical study.
Sources, limitations and citation
Financial observations come from Moderna SEC filings and earnings materials. Trial outcomes come from Merck/Moderna and ESMO; FDA approval status comes from the FDA. Market capitalization pairs the November 2 share price with a quoted basic share-count observation. All forecasts, probabilities, treatment prices and present values are analytical assumptions. Editorial Standards explain our evidence and correction approach.
- Moderna FY2025 Form 10-K — SEC / Moderna; December 31, 2025.
- Moderna June 2026 Form 10-Q — SEC / Moderna; June 30, 2026.
- Moderna Q2 2026 financial results and guidance — Moderna / SEC; July 31, 2026.
- Moderna convertible notes and capped calls, September 2026 Form 8-K — SEC / Moderna; September 1, 2026.
- INTerpath-001 Phase 3 melanoma results — Merck and Moderna; October 22, 2026.
- ESMO commentary on personalized mRNA melanoma Phase 3 data — ESMO; October 24, 2026.
- MFLUSIVA FDA vaccine approval — U.S. FDA; August 5, 2026.
- Moderna historical share price — Moderna Investor Relations; November 2, 2026.
- Moderna quoted basic shares outstanding — Stock Analysis; November 2, 2026.
- Moderna investor events and Q3 2026 earnings schedule — Moderna Investor Relations; November 3, 2026.
- Moderna oncology investor day presentations — Moderna Investor Relations; October 24, 2026.
See Research Standards for methods and reuse, or request a correction.